Download Figure S1 Subgroup analyses for the association between

Figure S1 Subgroup analyses for the association between postdiagnostic β-blocker use and all-cause and
cancer-specific mortality according to suffering from immortal time bias.
References
Assayag J, Pollak MN, Azoulay L (2014). Post-diagnostic use of beta-blockers and the risk of death in
patients with prostate cancer. Eur J Cancer 50:2838-2845.
Aydiner A, Ciftci R, Karabulut S, Kilic L (2013). Does beta-blocker therapy improve the survival of patients
with metastatic non-small cell lung cancer? Asian Pac J Cancer Prev 14:6109-6114.
Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, et al. (2013). Therapeutic effect of
beta-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat
140:567-575.
Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG (2013). Beta-blocker usage and breast
cancer survival: a nested case-control study within a UK Clinical Practice Research Datalink cohort.
Int J Epidemiol 42:1852-1861.
Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, et al. (2014). Perioperative beta-blocker use
and survival in lung cancer patients. J Clin Anesth 26:106-117.
Chae YK, Dimou A, Pierce S, Kantarjian H, Andreeff M (2014). The effect of calcium channel blockers on
the outcome of acute myeloid leukemia. Leuk Lymphoma 55:2822-2829.
De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P (2014). In reply--Effect of
beta-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and
death. Mayo Clin Proc 89:1167-1168.
Diaz ES, Karlan BY, Li AJ (2012). Impact of beta blockers on epithelial ovarian cancer survival. Gynecol
Oncol 127:375-378.
Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2014). Association between use of beta-blockers and
prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or
metastatic disease. Eur Urol 65:635-641.
Hicks BM, Murray LJ, Powe DG, Hughes CM, Cardwell CR (2013). beta-Blocker usage and colorectal
cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Ann Oncol 24:3100-3106.
Holmes MD, Hankinson SE, Feskanich D, Chen WY (2013). Beta blockers and angiotensin-converting
enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use.
Breast Cancer Res Treat 139:507-513.
Jansen L, Hoffmeister M, Arndt V, Chang-Claude J, Brenner H (2014). Stage-specific associations between
beta blocker use and prognosis after colorectal cancer. Cancer 120:1178-1186.
Livingstone E, Hollestein LM, van Herk-Sukel MP, van de Poll-Franse L, Nijsten T, Schadendorf D, et al.
(2013). beta-Blocker use and all-cause mortality of melanoma patients: results from a
population-based Dutch cohort study. Eur J Cancer 49:3863-3871.
McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, et al. (2014). Beta-blocker usage
after malignant melanoma diagnosis and survival: a population-based nested case-control study. Br J
Dermatol 170:930-938.
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. (2011).
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative
breast cancer. J Clin Oncol 29:2645-2652.
Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, et al. (2013). Improved survival
outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer
treated with definitive radiation therapy. Ann Oncol 24:1312-1319.
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN (2012). Treatment and outcomes of acute
coronary syndrome in the cancer population. Clin Cardiol 35:443-450.